<DOC>
	<DOCNO>NCT03025711</DOCNO>
	<brief_summary>The overall study objective evaluate effectiveness safety Trastuzumab emtansine ( T-DM1 ) Pertuzumab real-world disease condition Spain , specifically patient treat compassionate use early access program</brief_summary>
	<brief_title>Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine</brief_title>
	<detailed_description>This retrospective , non-interventional , non-comparative , observational cohort study / registry Spain . The study design reflect real-life clinical management patient HER2-positive MBC . Type frequency actual patient visit evaluation do routine clinical practice . The analysis efficacy safety result obtain patient receive pertuzumab TDM1 early access system utmost importance . These real-world patient advance breast cancer may different characteristic enrol clinical trial clinician must often extrapolate therapeutic decision fully support robust evidence .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Adult patient ( age â‰¥ 18 year enrolment ) HER2positive metastatic locally recurrent unresectable breast cancer treat Trastuzumab emtansine ( TDM1 ) Pertuzumab . Patients initiate Trastuzumab emtansine ( TDM1 ) Pertuzumab Spanish compassionate use early access program . Given characteristic study exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced HER2+ breast cancer</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>Compassionate use</keyword>
	<keyword>Early access program</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Safety</keyword>
</DOC>